الفهرس 
Probiotics versus placebo as a prophylaxis to prevent clinical manifestations of oral candidosis in patient’s with Sjogren’s syndrome
ContentsOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
Background: The prevalence of oral candidosis has been rising in more than 80% in patients with Sjogren{u2019}s syndrome. Probiotics can be considered an alternative approach to antifungal drugs for treatment and prophylaxis of oral candidosis. This study aimed to evaluate the short-term efficacy of Probiotics in reduction of oral Candidal growth in patients with Sjogren’s Syndrome. Methods: Thirty-two Sjogren{u2019}s syndrome patients were randomlyallocated in two groupsreceiving either Probiotics or placebo capsules twice daily for 5 weeks. Oral rinse solution samples were collected and Candidal levels were determined(CFU/mL) at baseline and after the 5-week experimental period. Pain, erythema and angular cheilitis were also assessed at baseline, 2, 4 and 5-weeks. Results: In the probiotic group there was a statistically significant reduction of candidal load from baseline to 5th week respectively [median 1950 CFU/ml ,interquartile range, 950 ; 4200 CFU/ml, ; median 999 CFU/ml ,interquartile range, 275 to 1925 CFU/ml, P{u2264} 0.005 ] While the change in candidal load at the same time period in the placebo group was not statistically significant [baseline median 1050 CFU/ml ,interquartile range, 1100 to 4750 CFU/ml ; 5th week median 1150 CFU/ml ,interquartile range, 849 to 3425 CFU/ml, P {u2265}0.005]. Conclusion: The probiotic product containing, L. acidophilus, L. bulgaricus, Streptococcus thermophilus and B. bifidumcan reduce Candidalgrowth in Sjogren’s syndrome patients suggesting that this multispecies probiotic can prevent oral candidiasis